Myomo Q1 2024 GAAP EPS $(0.10), Inline, Sales $3.754M Miss $4.071M Estimate

5/8/24 5:00:41 PM ET

Industrial Specialties

Health Care

Get the next $MYO alert in real time by email

Myomo (AMEX:MYO) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $3.754 million which missed the analyst consensus estimate of $4.071 million by 7.78 percent. This is a 8.91 percent increase over sales of $3.447 million the same period last year.

Get the next $MYO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYO

Date	Price Target	Rating	Analyst
7/31/2024	$7.00	Buy	Craig Hallum
5/20/2024	$7.00	Buy	Lake Street
12/15/2023	$6.50	Buy	H.C. Wainwright

More analyst ratings

Myomo Reports Record Third Quarter Financial and Operating Results
$9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Pro
11/6/24 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care
Myomo to Report Third Quarter Financial Results on November 6, 2024
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PI
10/30/24 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care
Myomo Reports Second Quarter 2024 Financial Results
Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2024. Financial and operational highlights for the second quarter of 2024 include the following (all comparisons are with the second quarter of 2023 unless otherwise indicated): Product revenue was $7.5 million, up 77%, with total revenue up 26% reflec
8/6/24 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care

Myomo Reports Record Third Quarter Financial and Operating Results
$9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Pro
11/6/24 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care
Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage
Blue Cross Blue Shield of Massachusetts and Paradigm together serve 3 million covered lives Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces it has entered into the first contracts that will allow MyoPro to be provided to patients covered by private insurance on an in-network basis. These new contracts are with Blue Cross Blue Shield of Massachusetts, a leading commercial and Medicare Advantage insurer, and Paradigm, a leading specialty care management organization serving workers' compensation and healthcare payers. Paradigm's contr
10/31/24 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care
Myomo to Report Third Quarter Financial Results on November 6, 2024
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PI
10/30/24 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care

$MYO
Leadership Updates

Live Leadership Updates

Myomo Appoints Heather Getz to its Board of Directors
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin
3/28/24 4:05:00 PM ET
$BFLY
$MYO
Medical Electronics
Health Care
Industrial Specialties
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research
1/30/23 4:05:00 PM ET
$MYO
Industrial Specialties
Health Care
Nordson Corporation Appoints Milton Morris to Board of Directors
Nordson Corporation (NASDAQ:NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors. Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board. "We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson's strength of understanding customer needs and bringing diversified precision technology solutions to market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further exp
9/15/22 4:30:00 PM ET
$BSX
$EMBC
$MYO
$NDSN
Medical/Dental Instruments
Health Care
Industrial Specialties
Industrial Machinery/Components

Lake Street Maintains Buy on Myomo, Raises Price Target to $7.5
Lake Street analyst Ben Haynor maintains Myomo (AMEX:MYO) with a Buy and raises the price target from $7 to $7.5.
7/9/24 1:50:48 PM ET
$MYO
Industrial Specialties
Health Care
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
7/9/24 12:59:31 PM ET
$ALB
$APLD
$ARLO
$BEEM
Major Chemicals
Industrials
Finance: Consumer Services
Finance
Gold Falls Over 1%; HilleVax Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday. The Dow traded down 0.12% to 39,329.47 while the NASDAQ rose 0.27% to 18,401.75. The S&P 500 also rose, gaining, 0.09% to 5,572.23. Check This Out: Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday. In trading on Monday, communication services shares fell by 0.9%. Top Headline Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Equities Trading UP
7/8/24 2:31:08 PM ET
$HLVX
$IVA
$LLY
$MORF
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Industrial Specialties

Myomo Q1 2024 GAAP EPS $(0.10), Inline, Sales $3.754M Miss $4.071M Estimate

Chat with this insight

Recent Analyst Ratings for $MYO

$MYO SEC Filings

SEC Form 10-Q filed by Myomo Inc.

Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Myomo Inc.

$MYO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 27% to 236,499 units (SEC Form 4)

Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 37% to 186,499 units (SEC Form 4)

Kirk Thomas F bought $155,000 worth of shares (50,000 units at $3.10), increasing direct ownership by 58% to 136,499 units (SEC Form 4)

$MYO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Myomo Inc.

Amendment: SEC Form SC 13G/A filed by Myomo Inc.

Amendment: SEC Form SC 13G/A filed by Myomo Inc.

$MYO Financials

Live finance-specific insights

$MYO Press Releases

Fastest customizable press release news feed in the world

Myomo Reports Record Third Quarter Financial and Operating Results

Myomo to Report Third Quarter Financial Results on November 6, 2024

Myomo Reports Second Quarter 2024 Financial Results

Myomo Reports Record Third Quarter Financial and Operating Results

Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage

Myomo to Report Third Quarter Financial Results on November 6, 2024

$MYO Leadership Updates

Live Leadership Updates

Myomo Appoints Heather Getz to its Board of Directors

Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

Nordson Corporation Appoints Milton Morris to Board of Directors

$MYO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Kovelman Harry covered exercise/tax liability with 121 shares, decreasing direct ownership by 0.10% to 123,314 units (SEC Form 4)

Chief Medical Officer Kovelman Harry covered exercise/tax liability with 121 shares, decreasing direct ownership by 0.10% to 123,435 units (SEC Form 4)

Chief Medical Officer Kovelman Harry sold $25,183 worth of shares (6,700 units at $3.76), decreasing direct ownership by 5% to 123,556 units (SEC Form 4)

$MYO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Craig Hallum initiated coverage on Myomo with a new price target

Lake Street initiated coverage on Myomo with a new price target

H.C. Wainwright initiated coverage on Myomo with a new price target

$MYO Market Insights

Live Market Insights

Lake Street Maintains Buy on Myomo, Raises Price Target to $7.5

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gold Falls Over 1%; HilleVax Shares Plunge

Recent Analyst Ratings for
$MYO

$MYO
SEC Filings

$MYO
Insider Purchases

$MYO
Large Ownership Changes

$MYO
Financials

$MYO
Press Releases

$MYO
Leadership Updates

$MYO
Insider Trading

$MYO
Analyst Ratings

$MYO
Market Insights